| abstract |
The invention relates to a composition in the form of an injectable aqueous solution having a pH of between 6.0 and 8.0 and comprising at least: a basal insulin having an isoelectric point (pI) of between 5.8 and 8.5; b) and a co-polyaminoacid consisting of glutamic or aspartic units as defined in the claims. In one mode of embodiment, the composition according to the invention is characterised in that the co-polyaminoacid bearing carboxylate charges and at least one hydrophobic radical Hy is selected from the co-polyaminoacids of formula (XXXb) in which: D is, independently, either a CH2 group (aspartic unit) or a CH2-CH2 group (glutamic unit); X is a cationic entity selected from the group comprising the alkaline cations; Rb and Rb', which are identical or different, are either a hydrophobic radical Hy, or a radical selected from the group consisting of an H, a linear acyl C2 to C10 group, a branched acyl C3 to C10 group, a benzyl, a terminal "amino acid" unit and a pyroglutamate, at least one of Rb and R'b being a hydrophobic radical Hy; Q and Hy have the above-mentioned designations; and n+m is the degree of polymerisation DP of the co-polyaminoacid, i.e. the average number of monomeric units per co-polyaminoacid chain and 5 =:; n + m =:; 250. |